for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

SAGE Therapeutics Inc

SAGE.O

Latest Trade

139.33USD

Change

-1.22(-0.87%)

Volume

371,064

Today's Range

138.38

 - 

142.28

52 Week Range

79.88

 - 

193.56

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
140.55
Open
140.44
Volume
371,064
3M AVG Volume
8.15
Today's High
142.28
Today's Low
138.38
52 Week High
193.56
52 Week Low
79.88
Shares Out (MIL)
51.66
Market Cap (MIL)
7,260.39
Forward P/E
-10.42
Dividend (Yield %)
--

Next Event

Q3 2019 SAGE Therapeutics Inc Earnings Call

Latest Developments

More

Sage Therapeutics Reports Qtrly Loss Per Share $3.28

Sage Says Sage-217 For Bipolar Depression Showed Rapid Improvement Versus Baseline In Phase 2 Study

Sage Therapeutics Announces U.S. Drug Enforcement Administration Scheduling Of Zulresso Injection

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About SAGE Therapeutics Inc

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company's next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.

Industry

Biotechnology & Drugs

Contact Info

215 1st St

+1.617.2998380

https://www.sagerx.com/

Executive Leadership

Kevin P. Starr

Independent Chairman of the Board

Jeffrey M. Jonas

President, Chief Executive Officer and Director

Kimi E. Iguchi

Chief Financial Officer, Treasurer

Anne Marie Cook

Senior Vice President, General Counsel, Secretary

Albert J. Robichaud

Chief Scientific Officer

Key Stats

1.68 mean rating - 19 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.1K

2019(E)

0.0K
EPS (USD)

2016

-4.750

2017

-7.090

2018

-8.080

2019(E)

-13.482
Price To Earnings (TTM)
--
Price To Sales (TTM)
4,506.76
Price To Book (MRQ)
6.01
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-52.88
Return on Equity (TTM)
-50.14

Latest News

Latest News

Sage gets U.S. approval for first postpartum depression therapy

The U.S. Food and Drug Administration on Tuesday approved Sage Therapeutics Inc's drug for postpartum depression, marking the first approval of a treatment specifically developed for the condition that affects a new mother's ability to care for herself or her baby.

CORRECTED-Sage gets U.S. approval for first postpartum depression therapy

The U.S. Food and Drug Administration on Tuesday approved https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm633919.htm Sage Therapeutics Inc's drug for postpartum depression, marking the first approval of a treatment specifically developed for the condition that...

Sage shares soar after oral postpartum depression treatment succeeds in trial

Sage Therapeutics Inc said on Monday its oral treatment for postpartum depression met the main goal of reducing symptoms of the condition, when compared to a placebo in a late-stage study, sending its shares up 33 percent.

Sage's oral postpartum depression treatment succeeds in late-stage study

Sage Therapeutics Inc said on Monday its oral treatment for postpartum depression met the main goal of reducing symptoms of the condition, when compared to a placebo in a late-stage study.

FDA panel recommends Sage's postpartum depression treatment

An advisory panel to the U.S. Food and Drug Administration on Friday recommended Sage Therapeutics Inc's experimental treatment for postpartum depression, saying the benefits of the drug outweighed risks.

Sage's postpartum depression treatment benefits outweigh risk: FDA panel

The benefits of Sage Therapeutics Inc's experimental treatment for postpartum depression outweigh risks, an advisory panel to the U.S. Food and Drug Administration said on Friday.

BRIEF-Sage Therapeutics Reports Quarterly Loss Per Share Of $1.68

* SAGE THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES UPDATE ON PIPELINE AND PROGRESS TOWARD LAUNCH READINESS

BRIEF-Sage Therapeutics Submits New Drug Application To U.S. FDA For Intravenous Brexanolone In The Treatment Of Postpartum Depression

* SAGE THERAPEUTICS SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR INTRAVENOUS BREXANOLONE IN THE TREATMENT OF POSTPARTUM DEPRESSION

BRIEF-Sage Therapeutics Qtrly Net Loss Per Share $1.75

* SAGE THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES PIPELINE UPDATE

BRIEF-Sage Therapeutics Prices Public Offering Of 3.5 Mln Shares At $164/Share

* PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 3.5 MILLION SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $164.00 PER SHARE Source text for Eikon: Further company coverage:

BRIEF-Sage Therapeutics Announces Proposed Public Offering Of Common Stock

* SAGE THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Sage Therapeutics Receives FDA Breakthrough Therapy Designation For Sage-217

* SAGE THERAPEUTICS RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR SAGE-217 FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER

BRIEF-Sage Therapeutics Says Sage-217 Met Primary Endpoint Of Improved Sleep Efficiency In Phase 1/2 Study

* SAGE THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM PLACEBO-CONTROLLED TRIAL IN A MODEL OF INSOMNIA DEMONSTRATING ACTIVITY ON SLEEP PARAMETERS AND SUPPORTING DEVELOPMENT OF SAGE-217 AS POTENTIAL TREATMENT FOR SLEEP DISORDERS

Sage shares surge as depression drug succeeds in mid-stage trial

Drug developer Sage Therapeutics Inc's shares soared as much as 85 percent to a record high on Thursday after its experimental drug to reduce the symptoms of depression succeeded in a mid-stage trial.

Sage's depression drug succeeds in mid-stage study

Sage Therapeutics Inc said on Thursday its drug to treat patients with moderate to severe depression met the main goal in a mid-stage study.

BRIEF-Sage Therapeutics prices public offering of 3.53 mln common shares at $85/share

* SAYS PUBLIC OFFERING OF 3.53 MILLION COMMON SHARES PRICED AT $85.00PER SHARE Source text for Eikon: Further company coverage:

BRIEF-Sage Therapeutics announces proposed public offering of common stock

* Sage Therapeutics announces proposed public offering of common stock

Sage soars as postpartum depression drug moves closer to approval

Sage Therapeutics Inc's shares surged to a record on Thursday after its postpartum depression drug succeeded in two late-stage studies, paving the way for it to bring to market the first FDA-approved treatment for the disorder.

REFILE-Sage Therapeutics postpartum depression drug meets main goal

Sage Therapeutics on Thursday said its drug to treat moderate and severe postpartum depression met the main goal in two late-stage studies.

BRIEF-Sage Therapeutics announces Brexanolone achieves primary endpoints

* Announces Brexanolone achieves primary endpoints in both phase 3 clinical trials in postpartum depression

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up